Designation of Methoxsalen (Uvadex) as an orphan drug - Terumo BCT Australia Pty Limited

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, was established to regulate the supply of therapeutic goods in Australia, ensuring they meet safety, quality, and efficacy standards. A significant gap this Act aimed to address was the lack of incentives for the development and availability of treatments for rare and neglected diseases, often referred to as orphan diseases. To address this gap, the Act includes provisions for the designation of orphan drugs, which are designed to encourage the research, development, and availability of treatments for conditions that affect a small number of people. In this context, the Therapeutic Goods Administration, through its delegated authority, designates specific drugs as orphan drugs to incentivise their development and ensure that Australians with rare conditions have access to necessary treatments. This legislative framework supports the broader policy objective of improving health outcomes for patients with rare diseases by facilitating the availability of targeted therapies.

Scope and Application

The Therapeutic Goods Act 1989, as amended by the designation of Methoxsalen (UVADEX) as an orphan drug, applies to the sponsor of the specified therapeutic good, in this case, Terumo BCT Australia Pty Limited, and to the therapeutic good itself, Methoxsalen (UVADEX), which is designated for the treatment of Cutaneous T-cell lymphomas (CTCL). The Act falls under the jurisdiction of the Commonwealth of Australia and is administered by the Therapeutic Goods Administration, an entity of the Department of Health. This designation under the Act and the subsequent regulation aims to encourage the development of treatments for rare diseases by providing incentives to pharmaceutical companies. The application of the orphan drug designation is geographically unrestricted within Australia, applying nationally across all states and territories. There are no explicit exclusions or exemptions mentioned in the text, although the orphan drug designation typically excludes drugs that are already widely used or have available alternative treatments. The application of the Act may be further extended or restricted through subordinate instruments, such as regulations or guidelines issued by the Therapeutic Goods Administration.

Key Provisions

In accordance with the Therapeutic Goods Act 1989, the designation of Methoxsalen (UVADEX) as an orphan drug (section 41-2) pertains to its use in the treatment of Cutaneous T-cell lymphomas (CTCL) (subsection 41-2(1)). This designation is made effective from 15 September 2015 by Dr. Anthony Gill, the Delegate of the Secretary, acting under the authority granted by subregulation 16J(2) of the Therapeutic Goods Regulations 1990. The specific dose form of Methoxsalen (UVADEX) designated for this therapeutic purpose is an injection solution (subsection 41-2(3)). The sponsor responsible for this therapeutic good is Terumo BCT Australia Pty Limited (subsection 41-2(5)). Under the Therapeutic Goods Act 1989, the obligations imposed by the orphan drug designation primarily concern the sponsor, Terumo BCT Australia Pty Limited. This includes the requirement to ensure that Methoxsalen (UVADEX) meets all regulatory standards for safety, efficacy, and quality, as stipulated by the Therapeutic Goods Administration (TGA). The sponsor must also comply with any additional obligations set forth in the Therapeutic Goods Regulations 1990, which govern the manufacturing, labelling, and distribution of therapeutic goods in Australia. Failure to comply with the provisions of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in both civil and criminal penalties. The TGA has the authority to impose fines on entities that breach the Act or the Regulations. The maximum penalties for these breaches are specified in the Act and can include substantial financial penalties for both individuals and corporate entities. Additionally, persistent or severe breaches may result in legal action, including prosecution, which could lead to further penalties as determined by a court of law. It is essential for the sponsor and other parties involved to adhere strictly to the legislative requirements to avoid these consequences.